Revvity (NYSE:RVTY) Stock Gets Price Target Boost from Barclays

Revvity (NYSE:RVTY) had its price target boosted by investment analysts at Barclays from $160.00 to $175.00 in a report released on Wednesday, Benzinga reports. The firm currently has an “equal weight” rating on the stock. Barclays‘s price objective indicates a potential upside of 8.23% from the stock’s current price.

RVTY has been the topic of a number of other reports. Evercore reaffirmed an “outperform” rating on shares of Revvity in a research report on Wednesday, August 5th. Royal Bank Of Canada lifted their price target on shares of Revvity from $135.00 to $172.00 and gave the company a “sector perform” rating in a research report on Wednesday. UBS Group started coverage on shares of Revvity in a research note on Wednesday, September 9th. They set a “neutral” rating and a $140.00 price objective on the stock. KeyCorp raised their target price on shares of Revvity from $125.00 to $165.00 and gave the company an “overweight” rating in a research note on Friday, September 4th. Finally, Zacks Research upgraded shares of Revvity from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Six investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $128.14.

Revvity Stock Down 1.1%

Shares of RVTY traded down $1.79 on Wednesday, reaching $161.69. The stock had a trading volume of 1,393,851 shares, compared to its average volume of 1,535,023. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. Revvity has a 12-month low of $81.22 and a 12-month high of $171.74. The firm has a market capitalization of $18.04 billion, a price-to-earnings ratio of 76.88, a price-to-earnings-growth ratio of 2.76 and a beta of 1.08. The company has a 50-day simple moving average of $145.89 and a 200-day simple moving average of $112.62.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $1.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.08. The business had revenue of $728.90 million during the quarter, compared to the consensus estimate of $694.73 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.18 earnings per share. Sell-side analysts predict that Revvity will post 5.36 EPS for the current year.

Insider Buying and Selling

In related news, insider Tajinder S. Vohra sold 7,330 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total value of $1,032,650.40. Following the sale, the insider owned 6,635 shares in the company, valued at approximately $934,738.80. This trade represents a 52.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Maxwell Krakowiak sold 1,631 shares of the firm’s stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $144.53, for a total transaction of $235,728.43. Following the completion of the sale, the insider owned 14,781 shares in the company, valued at $2,136,297.93. This represents a 9.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 9,045 shares of company stock valued at $1,281,439 over the last quarter. Company insiders own 0.85% of the company’s stock.

Hedge Funds Weigh In On Revvity

Hedge funds and other institutional investors have recently modified their holdings of the company. EdgePoint Investment Group Inc. grew its holdings in shares of Revvity by 3.1% in the first quarter. EdgePoint Investment Group Inc. now owns 8,800,863 shares of the company’s stock worth $771,044,000 after acquiring an additional 265,204 shares during the period. Jupiter Topco LLC bought a new position in Revvity in the second quarter valued at about $961,017,000. Janus Henderson Group PLC lifted its holdings in Revvity by 2.3% in the first quarter. Janus Henderson Group PLC now owns 8,348,127 shares of the company’s stock valued at $731,386,000 after acquiring an additional 186,956 shares during the period. BlackRock Inc. purchased a new position in Revvity in the second quarter worth about $852,070,000. Finally, State Street Corp boosted its position in Revvity by 0.8% in the second quarter. State Street Corp now owns 4,342,739 shares of the company’s stock worth $483,173,000 after purchasing an additional 32,426 shares during the last quarter. 86.65% of the stock is owned by institutional investors.

Trending Headlines about Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity reported Q3 adjusted EPS of $1.38, above the roughly $1.30 consensus, and revenue of $728.9 million versus estimates of about $694.7 million. Revenue grew 4.3% year over year, with Life Sciences strength and margin expansion contributing to the beat. The company also raised its 2026 outlook. Q3 earnings beat and outlook
• Positive Sentiment: CFRA upgraded RVTY from Hold to Buy, adding a favorable analyst view after the results. CFRA upgrade
• Neutral Sentiment: Royal Bank of Canada raised its price target from $135 to $172 but retained a Sector Perform rating; the new target implied about 6.3% upside at the cited share price. RBC price target
• Neutral Sentiment: Some coverage questioned whether the stock is now expensive after its earnings-driven run. That concern may limit further gains, particularly given the high valuation noted in the provided market data. Dividend and valuation discussion

About Revvity

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.